'Dubious' Benefit of Abemaciclib in Early Breast Cancer

With no overall survival benefit thus far, plus other concerns, editorialists "urge caution" before accepting abemaciclib as a standard of care in early breast cancer without mature data.
Medscape Medical News

source https://www.medscape.com/viewarticle/981217?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?